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Abstract
Doug Altman was a visionary leader and one of the most influential medical
statisticians of the last 40 years. Based on a presentation in the “Invited ses-
sion in memory of Doug Altman” at the 40th Annual Conference of the Inter-
national Society for Clinical Biostatistics (ISCB) in Leuven, Belgium and our
long-standing collaborations with Doug, we discuss his contributions to regres-
sionmodeling, reporting, prognosis research, aswell as somemore general issues
while acknowledging that we cannot cover thewhole spectrumofDoug’s consid-
erable methodological output. His statement “To maximize the benefit to society,
you need to not just do research but do it well” should be a driver for all researchers.
To improve current and future research, we aim to summarize Doug’s messages
for these three topics.
KEYWORDS
prognosis research, regression modeling, reporting
1 INTRODUCTION
Doug Altman, who passed away on June 3, 2018, was one of the most influential medical statisticians of the past 40 years.
His first reaction to this statement would probably have been, “But how can you make such a strong statement? Where
is the reliable and accessible evidence?” Although collecting convincing empirical evidence for strong statements is often
difficult and time-consuming, in this case the argument is easily made.
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Doug’s 1991 textbook Practical Statistics for Medical Research has sold more than 50,000 copies until 2015 (https:
//www.ndorms.ox.ac.uk/news/professor-doug-altman-receives-bmj-lifetime-achievement-award), making it one of the
most popular in this field (Altman, 1991a). In 1994, he published an editorial in the British Medical Journal (BMJ) entitled
“The scandal of poor medical research – we need less research, better research and research done for the right reasons”
(Altman, 1994). This short article has received relatively few citations compared with his other articles, at only several
hundred, but has profoundly affected the medical research community. There were earlier articles about the poor quality
of methodology and reporting in medical research, and Doug’s editorial appeared at the same time as many other critical
papers. But it was Doug’s clear message that resonated with the community: “As the system encourages poor research it is
the system that should be changed.We need less research, better research, and research done for the right reasons. Abandoning
using the number of publications as a measure of ability would be a start.”
In the years that followed, Doug stressed the key role of reporting guidelines and was one of the authors of the Lancet
series “Research: increasing value, reducing waste” published in 2014 (http://www.thelancet.com/series/research). In an
introductory comment, Kleinert andHorton (2014) stated “ . . . a far broader question should be posed: how should the entire
scientific enterprise change to produce reliable and accessible evidence that addresses the challenges faced by society and the
individuals who make up those societies?” There is no longer debate about whether medical science needs to change. The
question now is how it should change. More than 25 years ago, Doug strongly expressed the need to change the system
(Altman, 1994). In the years that followed, he pressed for improvements across many areas, including primary studies
and systematic reviews. Unfortunately, flaws in the application and interpretation of statistical analyses are still common
(Page et al., 2018).
Doug disagreed with the idea that the number of publications one amasses indicates the quality of one’s research.
However, the number of citations garnered by his papers does show the impressive reach of his work: as of January 16,
2020, Google Scholar records around 470,000 citations for his papers. About 70 of these papers have been cited more than
1,000 times. Even more astoundingly, Doug’s papers are currently the most cited in the Lancet, BMJ, Annals of Internal
Medicine, Statistical Methods in Medical Research, PLoS Medicine, Ultrasound in Obstetrics Gynecology, and Journal of
Biopharmaceutical Statistics.
Reliable evidence for our statement about Doug’s outstanding scientific contribution comes from the BMJ, for which
Doug served as Chief Statistical Editor formore than 20 years. In 2015, the BMJ honoredDougwith their LifetimeAchieve-
mentAward, saying: “DougAltmanhas been awarded the BMJLifetimeAchievementAward in recognition of his outstanding
contribution to the improvement of the scientific andmedical research literature. Professor Altman is one of theworld’s leading
experts in health research methodology, statistics and reporting and has spent his career working to improve transparency in
the conduct and reporting of health research. Over the years Professor Altman has led or been involved in developing many of
the reporting guidelines listed on the EQUATORwebsite. . . Altman has donemore than anybody to raise the standards ofmed-
ical publication and in the process has transformed the role of statistician from number cruncher to custodian of important
but often neglected values.” (http://www.equator-network.org/2015/05/07/professor-doug-altman-awarded-bmj-lifetime-
achievement-award/)
Doug was a brilliant collaborative researcher who worked with many national and international colleagues on an enor-
mous range of methodological and medical projects. Several published tributes give more detail than we could possibly
manage here (Collins, 2019; Deeks et al., 2018; Evans, 2018, Matthews, Chalmers, & Rothwell, 2018; Rennie, 2019; Triv-
ella, 2019; Watts, 2018). Although he was a pioneer of many novel statistical methods, Doug emphasized that a statisti-
cian’s biggest impact was often in ensuring adherence to basic statistical good practice. He championed practices, such as
focusing on effect estimates and confidence intervals rather than p-values, and analyzing continuous variables on their
continuous scale rather than categorizing them.
Doug’s collaborations were not just broad in topic. As noted at the 2018 Royal Statistical Society Annual Conference
tribute, (https://www.youtube.com/watch?v=f6k6LlqbqGA), Doug published with over 1,600 coauthors. The many coau-
thors came from many countries with the top 25 shown in Figure 1 (bottom), so even for the 25th country, South Africa,
eight of his papers were with authors from there.
In July 2019, one of us (Willi Sauerbrei) gave a presentation in the “Invited session in memory of Doug Altman” at
the 40th Annual Conference of the International Society for Clinical Biostatistics (ISCB) in Leuven, Belgium. For more
than 25 years, Willi collaborated with Doug and many other colleagues. After discussing the intended talk with some of
these collaborators, Willi decided to concentrate on regression modeling, reporting, and prognosis research, as his joint
work with Doug in these areas has had a major influence on his professional life. To broaden the view and illustrate
Doug’s profound influence on the current state of research, this article also includes contributions from other colleagues
who worked with Doug in at least one of these areas. For each of the topics discussed, we attempt to summarize the
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F IGURE 1 (Top) Doug’smost frequent coauthors, with size proportional to frequency, and (bottom) the countries that his coauthors came
from, with area proportional to frequency
messages and advice that Doug and his collaborators have given to the research community. Each topic is very broad, and
we consider only specific issues in which we have jointly published with Doug. For further topics and details, we refer the
reader to textbooks written or edited by Doug (Altman, 1991a; Altman, Machin, Bryant, & Gardner, 2000; Gore & Altman,
1982; Moher, Altman, Schulz, Simera, & Wager, 2014; Riley, van der Windt, Croft, & Moons, 2019) and to references given
in tributes mentioned above.
2 REGRESSIONMODELING
Doug’s jointworkwithWilli andMartin Schumacher on regressionmodeling startedwhenDoug sentMartin amanuscript
on bootstrap investigations for comments at the beginning of 1988. In the published version, Altman and Andersen (1989)
thankedMartin,Willi, Patrick Royston, and others for helpful comments on an earlier version.We could not have foreseen
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that Doug and Patrick’s later work (Royston &Altman, 1994) would lead to Patrick andWilli’s joint work onmultivariable
fractional polynomials (Royston & Sauerbrei, 2008).
Continuous variables play a key role in all areas of science in which empirical data are analyzed, and categorization
has been commonly used to handle continuous variables in multivariable regression models. In the 1990s, Doug and
others pointed to the critical issues raised by using cutpoints to categorize continuous variables (Altman, 1991b; Altman,
Lausen, Sauerbrei, & Schumacher, 1994). To improve this unfortunate situation, Doug and Patrick proposed the fractional
polynomial approach to determine the functional form of a continuous variable (Royston & Altman, 1994).
2.1 Bootstrap investigations of model stability
A major part of Doug’s methodological work was concentrated on regression modeling. All of his contributions were
motivated by concrete problems arising when analyzing a particular data set, both from projects where he was the statis-
tician and from papers that he discovered in published medical research. Doug centered his teaching and writing about
statistical methods in real-world examples. His 1991 book illustrates this approach, which may be one of the reasons for
its widespread use in the medical research community (Altman, 1991a; see also Section 6).
One example of these real-world problems was in a multinational placebo-controlled double-blind randomized trial
in patients with primary biliary cirrhosis (Christensen et al., 1985). The trial showed a significant treatment benefit if
(and only if) partially unbalanced covariates were adjusted for. The question arose whether this result was sensitive to the
choice of regressionmodel for the adjustment of the treatment effect and whether the data-dependent choice of covariates
would be stable when replicated. When a second study is not available, bootstrap resampling can be used to investigate
model stability. Building on work by Chen and George (1985), Doug and Per Kragh Andersen used bootstrap resampling
by integrating various variable selection approaches, so that an adjustment model was chosen in every bootstrap sample
(Altman & Andersen, 1989). They were able to provide clear evidence that the original model chosen for the trial analysis
and the resulting treatment effect estimates were valid. Willi and Martin extended this procedure by using the summary
results of bootstrap resampling to create a stable regressionmodel,which also addressed the correlation between covariates
(Sauerbrei & Schumacher, 1992).
At the time, these bootstrap resampling approaches were still rare. The importance of stability investigations is now
morewidely recognized (Heinze,Wallisch, &Dunkler, 2018), and resampling procedures are on the way to being routinely
used to investigate the stability of regression models, particularly when high-dimensional covariate data are involved.
2.2 Cutpoints to categorize continuous variables
Doug was always well acquainted with the medical literature, noticing trends in the application of specific statistical
methodology––and serious shortcomings––earlier than others. His work on categorizing continuous variables is one
example.
In 1991, Doug wrote a letter to the editor of the British Journal of Cancer (Altman, 1991b) to draw attention to issues in an
article on the role of the fraction of cells in the S-phase (SPF) for the prognosis of patients with breast cancer (Sigurdsson
et al., 1990). Doug observed that the authors had tried every possible cutpoint when categorizing SPF and reported the
“optimal” cutpoint leading to the most significant effect of SPF on disease-free survival, that is, the minimum p-value.
At the same time, Martin Schumacher and Berthold Lausen derived the asymptotic distribution of maximally selected
rank statistics (Lausen & Schumacher, 1992), building on the work by Miller and Siegmund (1982). As the maximally
selected log rank test is associated with the minimum p-value, this corresponds to the situation that Doug observed in the
aforementioned article. The type 1 error rate was, therefore, about 50%, not the 5% implied by the reported significance
test. By naively applying a cutoff that gives aminimum p-value, researchers can inflate a factor’s prognostic effect, when in
reality it may not be prognostic at all. Theminimum p-value can be corrected relatively simply by taking themaximization
of the test statistic or the minimization of the p-value into account.
During a meeting, Doug, Berthold Lausen, Martin, and Willi decided that this problem should be brought to the atten-
tion of a broader audience, particularly clinicians. We joined forces and wrote a manuscript exemplifying the problem
using data from a study of prognostic factors for primary breast cancer, using SPF as the factor of particular interest. We
searched for studies that dichotomized the continuous SPF value into two groups and investigated whether recurrence-
free survival times differed between the groups. We found 19 different cutpoints used for dichotomization, ranging from
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2.6 to 15.0. We also used this study to show that it is (nearly) always possible to define a “suitable” study population and
cutpoint that indicates that a factor has a significant prognostic effect. The resulting commentary in the Journal of the
National Cancer Institute (Altman et al., 1994) has often been used by editors to reject papers on prognostic factors that
use the minimum p-value.
However, despite this important early work highlighting the problems of categorizing continuous variables, this poor
practice continued to appear in the published literature. Doug, Willi, and Patrick wrote a paper in response that again
summarized the disadvantages of categorization and presented other approaches that make dichotomization of contin-
uous predictors unnecessary (Royston, Altman, & Sauerbrei, 2006). With the medical community in mind, Doug also
published a statistics note in the BMJ with Patrick, entitled “The cost of dichotomizing continuous variables” (Altman
& Royston, 2006). These papers remain highly pertinent, as sadly dichotomization is still rife in medical research.
2.3 Fractional polynomials
Royston and Altman (1994) introduced fractional polynomials as a useful extension of polynomial regression that could
be used to model the relationship between a continuous variable and an outcome. They proposed an extended family
of curves whose power terms are restricted to a small predefined set of integer and noninteger values. The powers are
selected so that conventional polynomials are a subset of the family. A suitable function selection procedure can be used
to check whether a linear function (in general the default) is adequate or whether a nonlinear fractional polynomial
function substantially improves model fit (Royston & Sauerbrei, 2008).
Although read to the Royal Statistical Society, the original paper was largely ignored by the statistical andmedical com-
munities. Spline-based approaches were preferred as they are much more flexible for deriving a functional form for one
continuous variable. Doug’s interests switched to other methodological issues, such as systematic reviews, meta-analysis,
and reporting. He did not further promote fractional polynomial methodology beyond onemore paper with Patrick (Roys-
ton & Altman, 1997) on using fractional polynomials to approximate smooth, continuous mathematical functions.
However, Willi realized that fractional polynomial methodology could be an important component in a multivariable
context. For many years, he had worked on variable selection, considering how continuous variables are handled to be a
key problem. Patrick and Willi combined their work and derived the multivariable fractional polynomial algorithm and
several extensions (Royston & Sauerbrei, 2008; Sauerbrei & Royston, 1999). Although other researchers have considered
extending the original proposal of the fractional polynomial power terms, practical experience has shown that the class of
fractional polynomial functions proposed by Royston and Altman (1994) is an excellent choice for the statistical analysis
of many data sets.
2.4 Age-related reference intervals
Reference intervals are predefined centiles of a clinically relevant variable Y. Loosely speaking, an individual is considered
normal if Y lies within the reference interval and potentially abnormal otherwise. Statistically, reference intervals are
relatively simple to construct when Y is considered alone but more challenging when the distribution of Y is associated
with a continuous predictor, often age.
Traditionally, age-related reference intervals are estimated by imposing cutpoints on age and applying univariate meth-
ods of centile estimation to the resulting age groups. The approach has several obvious and severe flaws.
The preferable alternative is to keep age continuous. Simple regression methods will fail to estimate reference intervals
accurately when the mean and higher moments of Y depend linearly or nonlinearly on age. Doug described a method
based on absolute residuals to estimate the age-related mean and SD of Y when the conditional distribution of Y given
age is normal (Gaussian) (Altman, 1993). In collaboration with Dr Lyn Chitty (University College London), Doug used
the absolute-residuals/FP method just mentioned to develop “charts” (graphs depicting gestational age-related reference
intervals) for a wide variety of fetal measurements (Altman & Chitty, 1994).
The general idea of extending conventional polynomials to fractional polynomialmodels arose fromDoug’s approach to
estimating the gestational age-related mean of fetal size. For instance, he found that restricted cubic functions of the form
𝛽1𝑥 + 𝛽2𝑥
3 provided an excellent, smooth fit to several measurements of fetal size. Discussion with Patrick Royston on
this topic led to joint work to develop and formalize fractional polynomial models and their inference (Royston &Altman,
1994).
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During the last decade of his life, Doug made substantial contributions to the design and analysis of the Interna-
tional Fetal and Newborn Growth Consortium for the 21st Century (INTERGROWTH-21st, a WHO-funded study of age-
related reference intervals for fetal size and growth, see https://www.wrh.ox.ac.uk/research/intergrowth-21st and refer-
ences therein).
One of Doug’s key principles of statistical modeling is clearly expressed in the statistical analysis section of the most
cited paper from this Consortium (Villar et al., 2014), 740 citations in Google Scholar (April 29, 2020). Authors discuss sev-
eral statistical methods, whichmay be used to construct standards to assess the size andweight of a newborn. They state as
criteria “Our aimwas to produce centiles that change smoothly with gestational age and that maximise simplicity without
compromising model fit.” Such charts are routinely used for monitoring fetal growth and development worldwide.
In two recent papers, standards for statistical methodology (Ohuma & Altman, 2019) and fetal growth (Papageorghiou
et al., 2018) were proposed. Doug’s name appears as a coauthor of many research reports on the INTERGROWTH-21st
project, four of which have more than 100 citations in Google Scholar (April 29, 2020).
2.5 COSMIC
During the 1990s, Doug, Patrick, Willi, Martin Schumacher, and Hans van Houwelingen focused on deeper issues in
regression modeling. Doug referred to these discussions as COSMIC (Cooperation On Statistical Modelling In Cancer)––
hewas quite extraordinary in comingupwith suitable acronyms to describe projects and often devoted considerable energy
to the process. Several papers resulted from this collaboration. Presentations under the COSMIC name were given, but no
paper was coauthored by all five members. However, the COSMIC discussions profoundly influenced all of their work.
Collaborative projects included building reliable and clinically valuable prognostic models in common types of cancer;
validating prognostic classification schemes in node-negative breast cancer patients; defining basic requirements for a
meta-analysis to investigate the prognostic effect of the different measurements of the plasminogen activation system in
breast cancer; and a simulation study to compare approaches formodel building in survival data with time-varying effects.
Only one paper clearly mentions the COSMIC group. In their highly cited article “What do we mean by validating a
prognostic model?” Altman and Royston (2000) acknowledged “We thank Hans van Houwelingen, Willi Sauerbrei and
Martin Schumacher (the other members of the COSMIC group), Marc Buyse and Jeremy Wyatt for helpful comments and
discussions.” The group members agreed that considering both statistical and clinical validity was sensible, but differed
on a few specific issues. Consequently, no paper was written under the name COSMIC.
Many papers authored or coauthored by a COSMICmember were influenced by discussions between the five members
and the PhD students who joined their meetings. The main topics of a 2-day meeting in 2005 illustrate the group’s broad
interests: pitfalls in interim analysis on longitudinal and survival data, reduced rank hazard regression versus frailty and
cure models, methods for estimating length of hospital stay (time-dependent bias), prognostic models in breast cancer,
the multivariable fractional polynomial-time algorithm, investigations of neural nets, model selection uncertainty, cross
validation andmodel selection, and a plea for good statistical practice when using high-dimensional data for classification
and prediction.
We talked about drafting a COSMIC position paper on some of these issues, but never managed it. However, COSMIC
discussions suggested thatworkwas needed to compare statistical procedures and formulate guidance for design and anal-
ysis. The discussions helped motivate the project that became the STRengthening Analytical Thinking for Observational
Studies (STRATOS) initiative (see Section 5.4), which included all five COSMIC members.
2.6 Mistakes in the interpretation of analyses
An error of interpretation led to Doug’s single most highly cited paper (Bland & Altman, 1986) with 45,483 citations on
Google Scholar and 33,659 on Web of Science (April 21, 2020). Martin Bland told Doug about a paper which had used
correlation as a measure of the agreement between two methods of measuring cardiac stroke index. Doug replied that
he had come across the same thing in blood pressure measurement. They agreed that a correlation coefficient could not
measure agreement: if one measurement were exactly twice the size of the other, for example, the correlation coefficient
would be 1.0, but the measurements would not agree. Doug looked for other examples and found two other inappropriate
methods of analysis, by paired t test and regression, testing the slope against 1.0, ignoring the regression dilution effect.
Martin drafted an introduction and discussion, including amathematical appendix. However, what should be done? They
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decided to start with the differences between measurements by the two methods. Having a set of differences, any statis-
tician would calculate the mean and standard deviation and it was a short step to saying that two (or the more accurate
figure, 1.96, preferred by Doug) standard deviations above and below the mean would provide a range within which 95%
of differences would lie, giving limits for the secondmeasurement. (For themethod to be valid, certain assumptions about
the distribution of the differences were of course needed.) Standard errors and confidence intervals for the limits of agree-
ment completed the paper. As a check on the constancy ofmean and standard deviation, they suggested plotting difference
against the mean of the two measurements by the two methods, which they thought was a standard approach for paired
t tests. They then proposed adding the 95% limits of agreement to the plot.
The idea was submitted for a conference of the Institute of Statisticians, now part of the Royal Statistical Society. Neither
Doug nor Martin had ever spoken at a statistical meeting before. Surprisingly, this simple approach was not known. Doug
and Martin wrote a paper, which was published in The Statistician, the journal of the Institute of Statisticians (Altman
& Bland, 1983). It was well received by statisticians, but ignored by researchers, who carried on correlating. Colleagues
suggested writing a version with a worked example for medical researchers. Martin collected some data by touring his
department with a peak expiratory flow meter and a mini meter, making two measurements by each method in random
order. He added himself and Doug to the data and also his parents and parents-in-law. The data were analyzed and formed
the core of a paper published by the Lancet (Bland & Altman, 1986).
To their great surprise and pleasure, the Lancet paper began to be cited, rapidly becoming a Citation Classic (Bland &
Altman, 1992), and eventually themost highly cited paper in the Lancet. In 2014, it was reported to be the 29thmost highly
cited paper in any journal in any field (Van Noorden, Maher, & Nuzzo, 2014). Although the Statistician paper also began
to be cited, the Lancet paper was seen as the one to cite and the approach became known as the Bland–Altman method.
In response to questions they were sent, Martin and Doug subsequently published further papers on the topic. A paper
discussing several extensions of the basic approach has more than 7,000 citations in Google Scholar (Bland & Altman,
1999). More information on the history of this work is available (Bland & Altman, 1995a).
3 REPORTING
Doug became interested in the quality of statistical reporting early in his career. While he was in his first post, at St.
Thomas’s Hospital Medical School, London, he and Martin Bland submitted a letter to the Lancet complaining about a
paper which had described 321 people as having been allocated to groups “more or less randomly” (Clarke & Campbell,
1975). They argued that allocation is either random or it is not; there is no intermediate state. The letter was not published,
but the point they were trying to make (albeit not very well) was a general one about research methods. They did get
a letter published criticizing statistical methods used in a Lancet article (Dritz et al., 1977), where association had been
mistaken for causation (Bland & Altman, 1977). The letter was the first of more than 100 joint scientific publications (see
Sections 2.6 and 5.1).
In 1993, a group of medical statisticians and others involved in trials and their reporting met in Ottawa, Canada, led by
DavidMoher and Stuart Pocock. Stuart had published an article (Pocock, Hughes, & Lee, 1987) on some of the problems in
how trials were reported, after he, Doug, Sheila Bird (nee Gore), and the lateMartin Gardner had suggested general guide-
lines in an earlier paper (Altman, Gore, Gardner, & Pocock, 1983). The Ottawa meeting resulted in the SORT guidelines
for reporting clinical trials (Andrew et al., 1994). The initiative merged with another to form the Consolidated Standards
of Reporting Trials (CONSORT) group, which published the first CONSORT reporting guideline in 1996. Although Doug
was not an author, he was a cosupervisor of coauthor Ken Schultz’s PhD (1994) and published with Ken and others on
reporting standards in trials and observational studies.
3.1 CONSORT and the EQUATOR Network
The CONSORT group met again in 1999. After careful revision, it published an updated version of the guidelines in 2001
(Moher, Schulz, & Altman, 2001). The paper states “David Moher, Ken Schulz, and Doug Altman participated in regular
conference calls, identified participants, contributed in theCONSORTmeetings, and drafted themanuscript.” TheCONSORT
group has been extraordinarily productive, not only in their own activities but also in encouragingwider involvement with
many others in different countries. The result has been further revisions of CONSORT, many extensions for specific trial
designs and clinical areas, and translations.
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The success of CONSORT led to reporting guidelines for other study designs, including the Strengthening the Reporting
of Observational Studies in Epidemiology (STROBE) statement for observational research (von Elm et al., 2007), the Pre-
ferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement for systematic reviews (Moher,
Liberati, Tetzlaff, & Altman, 2009), and extensions. Doug was involved in the development of many of these guidelines,
including STROBE and PRISMA. As has been done for many of the high-profile reporting guidelines, the PRISMA state-
ment was simultaneously published in six journals. It is currently Doug’s most highly cited paper, with well over 60,000
citations according to Google Scholar. Many of the CONSORT extensions are also highly cited, with extensions for cluster
trials (Campbell, Elbourne, & Altman, 2004), pragmatic trials (Zwarenstein et al., 2008), noninferiority trials (Piaggio,
Elbourne, Altman, Pocock, & Evans, 2006), and reporting harms (Ioannidis et al., 2004) all garnering more than 1,000
citations.
Despite CONSORT’s success, uptake of reporting guidelines by thewider research communitywas initially slow. Largely
through Doug’s initiative, the Enhancing the QUAlity and Transparency Of health Research (EQUATOR––another great
acronym!) Network was born in 2006 to promote reporting guidelines (https://www.equator-network.org/). The official
launch meeting photograph shows Doug wearing a tie, a most unusual occurrence! (https://www.equator-network.org/
about-us/history/). The EQUATOR Network holds a comprehensive database of reporting guidelines for health research
for any study design, numbering over 400 in early 2020. A summary of its goals and activities is given in Simera et al.
(2010). Of course, many researchers develop reporting guidelines. To improve and partly standardize the process, it is
important that guidance for such developers exists (Moher, Schulz, Simera, & Altman, 2010). As already mentioned in
the introduction, Doug was keen on the availability of reliable empirical evidence on an issue of interest and motivated
researchers to work with him on systematic reviews. For randomized controlled trials with statistically nonsignificant
primary outcomes, Boutron, Dutton, Ravaud, and Altman (2010) showed that the reporting and interpretation of findings
were frequently inconsistent with the results.
3.2 REMARK
Simon and Altman (1994) published a seminal paper about statistical aspects of prognostic factor studies, followed by a
paper aboutmethodological challenges (Altman&Lyman, 1998). These papers influenced general thinking about the poor
quality of prognostic research. Despite years of research and hundreds of published reports on tumormarkers in oncology,
only a small number of markers have proven clinically useful (Hall et al 1999; Hayes et al., 1996; McShane et al., 2000).
To rectify this unfortunate situation, in 2000, the US National Cancer Institute (NCI) and the European Organization for
Research andTreatment of Cancer (EORTC) organized the First InternationalMeeting onCancerDiagnostics (titled From
Discovery to Clinical Practice: Diagnostic Innovation, Implementation, and Evaluation). The purpose of the meeting was
to discuss issues, accomplishments, and barriers in the field of cancer diagnostics.
Inadequate reporting was identified as a key issue. Doug (for EORTC) and Lisa McShane (for NCI) were selected as
chairs of a project to derive guidelines for reporting tumor marker prognostic studies. Doug invited Willi to join a small
group of researchers to work on these guidelines. Despite being skeptical about work on guidance for reporting, Willi
joined the project. The REporting recommendations for tumor MARKer prognostic studies (REMARK) guidelines were
initially published in 2005 in five journals (Journal of the National Cancer Institute, the British Journal of Cancer, the
European Journal of Cancer, the Journal of Clinical Oncology, and Nature Clinical Practice Oncology), then again in 2006
in a further two journals (Breast Cancer Research and Treatment and Experimental Oncology) (McShane et al., 2005).
To enlarge on the 20-item REMARK checklist, four of the coauthors created an Explanation and Elaboration (E&E)
paper. Doug had had experience with E&E papers for other reporting guidelines. Such papers explain each item of the
reporting guideline in detail and give published examples of good reporting. Putting together, the REMARK E&E was no
simple task. The aim was to provide a comprehensive overview to educate researchers on good reporting and provide a
valuable compendium of issues to consider when designing, conducting, and analyzing tumor marker studies and prog-
nostic studies in medicine in general. For example, Item 10 of the checklist states that authors should report all statistical
methods used. The E&E lists several aspects of analysis that could be reported under eight subheadings. For somemethod-
ological issues, additional details were provided in five boxes, for example, missing data, subgroups, and interactions. The
authors also developed the two-part REMARKprofile for structured reporting of all analyses planned and undertaken (see
Section 5.3 for further details). Before submitting the paper for publication, Doug insisted on sending it to several expe-
rienced colleagues for comment. The REMARK E&E project took several years to complete and was finally published in
2012 (Altman, McShane, Sauerbrei, & Taube, 2012).
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Not only did Doug develop reporting guidelines, but he was also involved in many systematic reviews evaluating the
reporting quality of primary research against reporting guidelines. He was a driving force behind a project illustrating
reporting quality in tumor marker studies before REMARK was published (Mallett, Timmer, Sauerbrei, & Altman, 2010).
The studywas repeated some years later to assess the guideline’s influence on the quality of reporting (Sekula,Mallett, Alt-
man, & Sauerbrei, 2017). Alongside this comparison over time, the authors also compared the reporting quality of papers
that did and did not cite REMARK, matched by journal and year. Ten of the 20 items were used to define a summary score
of reporting quality. Although there was no worthwhile difference between articles that did and did not cite REMARK,
there was a slight improvement in reporting quality over time. Serious weaknesses in the quality of reporting remained.
Not all the papers that cited REMARK actually applied it correctly.
3.3 TRIPOD
Doug continued work on improving the reporting of prognostic research beyond tumormarker studies and REMARK. He
was involved in numerous systematic reviews evaluating the quality of reporting of prognostic models (Burton et al., 2004;
Mallett, Royston, Dutton,Waters, & Altman, 2010; Mallett, Royston,Waters, Dutton, & Altman, 2010). In response to poor
reporting described in these reviews and others byGaryCollins andKarelMoons, the TRIPOD initiativewas established in
2010, led by Gary, Karel, Johannes Reitsma, and Doug. Once again, Doug coined the acronym, TRIPOD, for the initiative,
standing for Transparent Reporting of a multivariable prediction models for Individual Prognosis Or Diagnosis.
Between 2010 and Doug’s last overseas visit in April 2018, the four of us met two to three times each year, alternating
between Oxford and Utrecht. The TRIPOD initiative aimed to provide guidance on reporting prediction model studies. In
2015, we published the TRIPOD statement simultaneously in 11 journals (Annals of Internal Medicine, British Journal of
Obstetrics and Gynecology, BMCMedicine, BMJ, British Journal of Cancer, British Journal of Surgery, Circulation, Diabetic
Medicine, European Journal of Clinical Investigation, European Urology, and Journal of Clinical Epidemiology; Collins,
Reitsma, Altman, & Moons, 2015), with editorials and commentaries appearing elsewhere.
Accompanying the checklist was a 73-page E&E paper with 532 references that provided the rationale for each item
in the checklist, evidence of poor reporting, and examples of good reporting (Moons et al., 2015). Although the aim of
the TRIPOD statement was to improve reporting, the E&E document also aimed to improve methodological quality. It
contained methodological considerations, highlighting statistical practices to avoid and consider (e.g., handling missing
data, appropriate treatment of continuous variables, and preferred internal validation procedures). Subsequent activities
by the TRIPOD group initiated with Doug’s involvement include strategies and guidance to assess andmonitor adherence
to TRIPOD (Heus et al., 2018; Heus et al., 2019), TRIPOD for abstracts, TRIPOD for electronic health records data and
individual participant meta-analysis, and, more recently, TRIPOD for machine learning (Collins & Moons, 2019).
The success of the TRIPOD initiative, now also including Richard Riley, led to numerous methodological collabora-
tions on sample size, how to handle continuous predictors, how to handle treatments, external validation, and systematic
reviews of prediction model studies. Doug played a prominent role in generating ideas and providing the critical feedback
and insights that only someone of his stature and experience could give. His legacy within the group will continue to be
felt and appreciated into the future.
4 PROGNOSIS RESEARCH
Doug’s longstanding interest in improving prognostic (or prediction) model research extended beyond fractional poly-
nomials (Section 2.3) and reporting (Sections 3.2 and 3.3) to include sample size (Collins, Ogundimu, Cook, Manach, &
Altman, 2016; Ogundimu, Altman, & Collins, 2016; van Smeden et al., 2016; van Smeden et al., 2019), handling of missing
data (Burton & Altman, 2004), and validation (Royston & Altman, 2013). In the 1990s, he coauthored articles signaling
problems in the design, analysis, and reporting of prognosis research, often focusing on oncology (Altman & Lyman, 1998;
Simon & Altman, 1994; Wyatt & Altman, 1995). Sadly, over 20 years later, many of the issues identified are still apparent
in prognosis research, particularly small sample sizes, inappropriate analysis methods, and poor and selective reporting.
Doug would often share examples of poor practice with his colleagues, using them as fuel to keep pushing forward mes-
sages to improve the field.
One of Doug’s biggest concerns was the effect of prognosis studies on subsequent systematic reviews, as he feared that
poor quality and biased reporting of primary studies would limit the conclusions of subsequent systematic reviews aiming
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to summarize multiple prognosis studies. Subsequent empirical evaluations have shown his concerns were justified,
with many systematic reviews recommending improvements to primary research studies (Riley et al., 2013), rather than
recommending using existing prognostic findings in clinical practice. Doug’s much earlier statement (Altman, 2001). is
still highly pertinent: “As a consequence of the poor quality of research, prognostic markers may remain under investigation
for many years after initial studies without any resolution of the uncertainty. Multiple separate and uncoordinated studies
may actually delay the process of defining the role of prognostic markers.”
Starting in 2004, Doug and colleagues, including Richard, initiated the Cochrane Prognosis Methods Group (Riley
et al., 2007). The group brought together researchers and clinicians with an interest in generating best evidence to
improve the pathways of prognostic research and facilitate evidence-based prognosis results to inform research, service
development, policy, and practice (https://methods.cochrane.org/prognosis/). Doug worked with the group to deliver
guidance for conducting reviews of overall prognosis, prognostic factors, and prognostic models (Debray et al., 2017;
Riley, Moons et al., 2019).
In recent years, Doug was delighted that exemplar prognosis reviews were being initiated by Cochrane, some of which
have now been published in the Cochrane library. These reviews are a testament to Doug’s drive and foresight. He was
also the senior researcher in one of the first individual participant data (IPD) meta-analyses to examine the prognostic
value of a biomarker. Using IPD from published and unpublished studies, the work showed no clear evidence that micro-
vessel density was a prognostic marker in patients with lung cancer, which contradicted a previous systematic review and
meta-analysis based only on published results (Trivella, Pezzella, Pastorino, Harris, & Altman, 2007). Doug also used the
project to highlight the challenges of obtaining IPD (Altman, Trivella, Pezzella, Harris, & Pastorino, 2006) and encouraged
greater data-sharing initiatives.
Another major contribution to the prognosis field was the PROGRESS (PROGnosis RESearch Strategy) initiative, led
by Doug, Richard, and Harry Hemingway. This group published a series of papers in the BMJ and PLoS Medicine that
outlined a framework for prognosis research under four themes: overall prognosis, prognostic factors, prognostic models,
and predictors of treatment effect (Hemingway et al., 2013; Hingorani et al., 2013; Riley et al., 2013; Steyerberg et al., 2013).
The aimwas to help researchers appreciate how each formof prognosis research can be used to informand improve patient
outcomes, and to identify good practice for the design, analysis, and interpretation of such studies. The PROGRESS group’s
work laid the foundation for the bookPrognosis Research inHealthcare: concepts,methods and impact, published byOxford
University Press in 2019 (Riley, van derWindt et al., 2019). Doug coauthored three chapters, and the book was dedicated to
him (“For Doug, our inspiration to improve prognosis research”). However, much work remains. We encourage researchers
to take up Doug’s baton and strive for the high-quality prognosis studies he so desired to see.
5 DOUG’S MESSAGES
For the three topics discussed, we illustrate the influence and the messages of Doug on different time scales. This graph
shows impressively that it takes a long time to make changes in the research culture. There were 20 years between Doug’s
“scandal” letter and the Lancet series “Research: increase value, reduce waste.” About 30 years ago, he wrote about prob-
lems caused by categorizing continuous variables. Meanwhile, many papers have been published on this issue but cat-
egorization is still a very popular approach in many analyses. Nowadays, the EQUATOR network is well accepted but
Doug and others struggled many years to get funding for a center working on reporting guidelines. A key step was the
establishment of the Centre for Statistics in Medicine (CSM) in Oxford, in September 1995.
The time scale is dominated by joint work Doug did with one or more of us (Figure 2). Therefore, it also illustrates a
specific type of publication bias. However, themain aim is to bring Doug’s messages for these topics to a broader audience.
Specifically, his more recent work may not be known to many researchers. The four sections discuss aspects of medical
research that Doug particularly focused on and contributed to in a major way because he perceived a pressing need for
improvement. We hope that his statement “To maximize the benefit to society, you need to not just do research but do it
well” is a driver for all researchers.
5.1 Education for statistics in practice
Following critical articles stating that much that is published in medical journals is statistically poor or even wrong
(Altman, 1982; Altman et al., 1983), the British Medical Journal, asked Doug to contribute a series of short pieces on
SAUERBREI et al. 11
F
IG
U
R
E
2
Ti
m
es
ca
le
sh
ow
in
g
ke
y
pa
pe
rs
an
d
ev
en
ts
fo
rt
he
th
re
et
op
ic
sd
isc
us
se
d
an
d
fo
rg
en
er
al
iss
ue
s.
Z+
(x
y)
m
ea
ns
th
at
it
is
a
pa
pe
rf
ro
m
Z
w
ith
m
or
et
ha
n
tw
o
au
th
or
s,
pu
bl
ish
ed
in
th
ey
ea
rx
y.
Sh
or
tp
hr
as
es
m
ay
he
lp
ge
tti
ng
a
ro
ug
h
ov
er
vi
ew
,a
tl
ea
st
it
w
ill
he
lp
fin
di
ng
th
er
ef
er
en
ce
.
12 SAUERBREI et al.
statistics and research for the journal. These were described as “fillers,” which would occupy spare parts of pages (of
the then paper journal) at the end of research articles. They would not be refereed but Doug would take responsibility
for them. He thought that this was a great opportunity to educate researchers with lower levels of statistical training,
experience, and interest in basic statistical issues. To help protect him from mistakes (!), he suggested Martin Bland
as a coauthor. They had already published 15 statistical articles and letters together, including two citation classics on
agreement between methods of measurement (Altman & Bland, 1983; Bland & Altman, 1986; see Section 2.6).
The first StatisticsNotewas published in 1994 (Bland&Altman, 1994). In it, randomly generated numberswith five pairs
of observations on each of five “subjects” were analyzed in two ways: using subject means for each variable and mixing
observations from different “subjects” indiscriminately. The analysis of subject means found no significant correlation, as
wewould expect, there being no underlying relationship. The analysis of 25 observations produced a correlation coefficient
closer to zero, but statistically significant. The incorrect nature of the analysis was both illustrated and explained. This was
followed by eight more Statistics Notes in 1994, on regression toward the mean, diagnostic tests, one- and two-sided tests
of significance, centiles and other quantiles, and matching. They continued to appear fitfully until Doug’s death in 2018.
Doug andMartin agreed that other authors could be included, but that either Doug or Martin would always be an author.
The other of the pair would check the Note and take editorial responsibility for it. Doug was much the more energetic
collaborator and coauthored 13 Notes with eight colleagues, Martin only managing five Notes with one colleague. Doug
was a natural collaborator.
The Notes began to be cited. According to Web of Science (WoS), at April 21, 2020, the first (Bland & Altman, 1994)
had been cited 145 times. The most highly cited was an explanation of Cronbach’s alpha coefficient (Bland & Altman,
1997), with 2,053 citations on WoS. The second was on the Bonferroni method for multiple significance tests (Bland &
Altman, 1995b), with 1,968 citations, and the third was on sensitivity and specificity of diagnostic tests (Altman & Bland,
1994), with 1,063 citations. The final Note, in 2018, was by Doug and MohammadMansournia, on population attributable
fraction (Mansournia & Altman, 2018), cited 34 times. A full list of BMJ Statistics Notes, with links to their text in BMJ,
can be found at https://www-users.york.ac.uk/∼mb55/pubs/pbstnote.htm.
In addition to the BMJ series with Martin, Doug made sterling efforts to educate researchers in better use of statistical
methods. Many summaries around specific statistical issues are given in the “explanation and elaboration” papers
associated with reporting guidelines (see the third paragraphs in 3.2 [REMARK], 3.3 [TRIPOD], and in other E&E
papers). Amongmany other relevant papers, we refer the reader to one that Doug and six eminent colleagues wrote about
statistical tests, p-values, confidence intervals, and power, all key issues in statistical methodology (Greenland et al.,
2016).
5.2 Reporting of prognosis research
With his longstanding interests in evaluating and improving scientific reporting and in statistical considerations in studies
of prognosis, Doug was naturally interested in the scientific reporting of prognosis research. This was emphasized by his
involvement in the REMARK and TRIPOD reporting guideline initiatives to improve prognosis research. Doug’s motiva-
tion to improve reporting of prognosis research was to reduce waste from incomplete or unusable reports (Glasziou et al.,
2014). Inadequate or incomplete reporting limits an assessment of a study’s methods and findings, bringing into question
the usability of the research. This theme was present in much of Doug’s published work.
It is a longway from the first single studies to an evidence-based assessment of the prognostic value of amarker. In 2006,
Doug and colleagues stressed the key role of IPD meta-analysis and stated that registration of prognostic marker studies
would help to reduce publication bias (Sauerbrei, Holländer, Riley, &Altman, 2006). In a subsequent paperDoug, Richard,
andWilli discussed the consequences of poor reporting of prognostic factor studies, including highlighting deficiencies in
statistical analysis (e.g., dichotomizing continuous markers) (Riley, Sauerbrei, & Altman, 2009). With colleagues, Doug
also wrote about the problems of selective reporting (Rifai, Altman, & Bossuyt, 2008), publication bias, and across-study
heterogeneity, which are rife in prognosis studies and prevent formal evidence synthesis (Altman & Riley, 2005). In sys-
tematic reviews andmeta-analyses, Yavchitz et al. (2016) identified 39 types of spin, which they classify and rank according
to the severity. In 2018, Doug and his colleagues at the Centre for Statistics in Medicine evaluated reporting and levels of
overinterpretation of prognostic factors in oncology (Kempf et al., 2018). They identified misleading reporting strategies
used by authors that could influence how readers interpret study findings. Doug published extensively on the reporting
andmethodological conduct of prognostic factor research, both highlighting the problems of poor reporting and providing
guidance for researchers to do better research (Riley, Moons et al., 2019).
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In parallel to his interests in studies of single prognosticmarkers, Dougwas also interested in prognosticmodels––using
multiple prognostic covariates to make individualized predictions. He was involved in numerous systematic reviews eval-
uating the methodological conduct and reporting of prognostic models (Altman, 2009; Bouwmeester et al., 2012; Collins
et al., 2014; Mallett et al., 2010). These reviews and many others have highlighted the problems that result from poor
reporting. For example, an individualized prediction of prognosis requires a fully reported model. However, these reviews
have all highlighted that models are often incompletely reported, so cannot be used. The resulting research waste could
have been avoided by proper reporting.
An interesting consequence of the failure to report a prognostic model arose when Gary and Doug externally validated
the QFracture score. They sought to independently evaluate the predictive accuracy of QFracture, a model to predict
10-year risk of osteoporotic fracture of any of several bones, including the hip, and compare it to another leading
model in this area, FRAX (Collins & Altman, 2011). At the time, both models were being considered for inclusion in
clinical guidelines. As Doug and Gary wrote in their resulting paper: “The details and source code for the calculation
of an individual’s risk using FRAX has to date not been published or released for independent evaluation. We sought to
compare QFractureScores against FRAX for the hip fracture endpoint but our requests for an independent head to head
comparison were not taken up by the developers of FRAX.” In this instance, the lack of reporting of the model meant that
the two leading models in this clinical area could not be directly compared, complicating the decision of which model
to use.
In addition to reporting guidelines, Doug encouraged registration of prognosis studies (such as on clinicaltrials.gov) and
publishing protocols to reduce selective reporting, improve transparency, and promote data sharing (Altman, 2014; Andre
et al., 2011; Peat et al., 2014; Riley et al., 2009). In response, a journal called Diagnostic and Prognostic Research (diagno-
prognres.biomedcentral.com) was established with Gary as editor-in-chief and Doug, Richard, Willi, and many others on
the editorial board. The journal regularly publishes protocols for all types of prognosis research, including primary studies
of prognostic factors and models, evidence synthesis, and methodological studies. Doug played an important role in early
discussions with Gary to establish this journal.
5.3 Structured reporting and study registration
Many papers have provided empirical evidence of bad reporting (Heus et al., 2018; Mallett et al., 2010; Sekula et al., 2017).
It is evident that simply developing reporting guidelines and providing detailed background information is not enough
to solve the problem. E&E papers are (too) long and do not seem to reach most of the relevant researchers. To alleviate
the situation, Sauerbrei, Taube, McShane, Cavenagh, and Altman (2018) produced a considerably abridged version of the
detailed REMARK E&E paper. The paper aims to serve as a brief guide to key issues for investigators planning tumor
marker prognostic studies, and can be easily translated into other languages. Translations will help to bring key infor-
mation to a larger global audience. Sauerbrei et al. (2018) emphasized that several cancer journals ask authors to follow
the REMARK recommendations in their instructions to authors, and encouraged more journals to follow this example.
Action by authors, reviewers, and editors is needed to improve reporting.
In 2014, Doug and colleagues published a book giving an overview of why reporting guidelines are needed and summa-
rizing some of the major reporting guidelines, Guidelines for Reporting Health Research – a user’s manual (Moher et al.,
2014). Doug was a coauthor of 12 of the 29 chapters. A list of “creator’s preferred bits” is included for each summarized
guideline. For REMARK, Altman, McShane, Sauerbrei, Taube, and Cavenagh (2014) emphasized that estimates with con-
fidence intervals need to be given, regardless of statistical significance of the estimate. They also stressed the importance
of structured reporting, as proposed in the two-part REMARK profile.
The upper part of the profile gives details about the patient population, how the marker was handled in the analysis,
which other variables were available, and key information about the outcome. The lower part of the profile details each
analysis performed, including the number of patients and events and the amount of data available for each analysis.
Although subgroup analyses are often conducted, relevant information, such as the effective sample size, is often omitted.
Defining all details of the analysis part prospectively when designing a studywould correspond to a very detailed statistical
analysis plan (SAP). Guidelines for the content of SAPs have been proposed for clinical trials (Gamble et al., 2017). An
SAP may have to be modified, for example, if important assumptions are violated. Any changes could also be noted in
the paper’s REMARK profile. Readers would then see all analyses and would be able to distinguish between preplanned
analyses and data-dependent modifications or additional analyses.
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The REMARK E&E paper (Altman et al., 2012) followed Doug’s principle that “everything needs to be as simple as pos-
sible,” presenting just two simple profiles that illustrate the key issues. Winzer, Buchholz, Schumacher, and Sauerbrei
(2016) extended the profile by proposing additional information about the initial data analysis (Huebner, Vach, le Cessie,
Schmidt, & Lusa, 2020) and checking relevant assumptions. Similar profiles have recently been developed for other types
of studies.
In an editorial on a paper providing empirical evidence of the seriousness of selective reporting biases in cancer prog-
nostic factor studies (Kyzas, Loizou, & Ioannidis, 2005), McShane, Altman, and Sauerbrei (2005) stated that “The number
of cancer prognosticmarkers that have been validated as clinically useful is pitifully small, despite decades of effort andmoney
invested in marker research. For nearly all markers, the product has been a collection of studies that are difficult to interpret
because of inconsistencies in conclusions or a lack of comparability. Small, underpowered studies; poor study design; varying
and sometimes inappropriate statistical analyses; and differences in assaymethods or endpoint definitions are but a few of the
explanations that have been offered for this disappointing state of affairs.” Further empirical evidence of selective reporting
biases was provided by Kyzas, Denaxa-Kyza, and Ioannidis (2007). They evaluated about 2,000 articles on cancer prognos-
tic markers and showed that almost all of the articles reported statistically significant results. Publication bias is clearly
an important issue in marker research.
Publication bias and hiddenmultiple-hypothesis testing distort the assessment of the true value of markers. Publication
bias from preferential reporting of “positive” findings is well recognized. Hidden multihypothesis testing arises when
several biomarkers are tested by different teams using the same samples. Themore hypotheses (i.e., biomarker association
with outcome) that are tested, the greater the risk of false-positive findings. These biases inflate the potential clinical
validity and utility of published biomarkers, while negative results often remain hidden. The REMARK profile aims to
facilitate more complete and better reporting of all analyses. Better reporting, the use of trial registries, and preregistration
of all phase II and III trials will substantially improve prognosis research (Altman, 2014; Andre et al., 2011; Peat et al., 2014;
Riley et al., 2009).
5.4 Standardization and guidance for analysis
With the series in the BMJ, Doug andMartin Bland (see Section 5.1) aimed to provide basic information on statistical issues
to researchers with limited knowledge in statistical methodology. However, weakness in many analyses clearly showed
that many experienced statisticians also need guidance and that more standardization is required.
Doug emphasized the importance of these issues earlier than most other methodological researchers, as evidenced by
his early role in groups developing reporting guideline and other initiatives. Work on REMARK (see Section 3.2) and
COSMIC group discussions (see Section 2.5) showed that guidance for analysis was urgently needed. In 2011, Willi was
mandated by the Epidemiology Subcommittee (EpidSC) of ISCB to start a project to create guidance for the analyses of
observational data. Doug was a strong supporter of the project from the beginning, discussing the project’s motivation,
mission, structure, and main aims with Willi. The result of discussions among many researchers, including all COSMIC
members, was the launch of the STRATOS initiative at ISCB 2013. Doug was the only speaker at the first STRATOS mini-
symposiumwho gave two presentations (a general talk and a talk on behalf of the topic group TG5 “Study design”). Hewas
one of five authors of a paper introducing STRATOS (Sauerbrei, Abrahamowicz, Altman, le Cessie, & Carpenter, 2014),
which stated: “The over-arching objective is to provide accessible and accurate guidance for data analysts with different levels
of statistical education and interests, taking into account the differences in their training and experience.” Twenty years ear-
lier, Doug stressed in his “scandal” article (Altman, 1994) that: “Statistical refereeing is a form of firefighting. The time spent
refereeing medical papers (often for little or no reward) would be much better spent in education and in direct participation
in research as a member of the research team. There is, though, a serious shortage of statisticians to teach and, especially, to
participate in research.”
Doug was a member of the STRATOS Steering Group and TG5, and cochaired with Willi the Contact Organizations
panel. The first TG5 paper appeared soon after his death (Gail et al., 2019). In a report introducing the Design topic group
to members of the International Biometric Society, Gail and Cadarette wrote “Doug Altman was an inspirational leader in
TG5, and his contributions continue to influence our thinking” (Gail & Cadarette, 2019).
Beside of a small part of Doug’s CONSORTwork on reporting guidelines, we hardly touched his contributions to clinical
trials. Nowadays, guidance is available formany parts of trials but until recently several gaps existed.With colleagues,Doug
proposed standards for the development of a core outcome set and for the content of SAPs (Gamble et al., 2017; Kirkham
et al., 2017; Williamson et al., 2017). Such guidance is needed to support transparency and reproducibility.
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6 DOUG ALTMAN––A PERSONAL NOTE BY PATRICK ROYSTON
I first met Doug in late 1976 when he and the late Michael Healy interviewed me for my first job in medical statistics, at
the then UK Medical Research Council Clinical Research Centre (CRC) in north-west London. I was fortunate enough
to be appointed to the post, which largely involved providing a statistical consultancy service to researchers at the CRC.
Doug had already worked there for about a year in the Division of Computing and Statistics.
We worked as consulting statisticians learning an enormous amount about the practicalities and pitfalls of developing
and executing medical research projects. I believe much of Doug’s burning desire to improve the quality of the many
aspects of statistics in medical research arose from this experience of the research “coal-face.” One thing that became
increasingly apparent to uswas howweak (or nonexistent) was the planning ofmedical research, particularly study design
and analysis of the resulting data. Our first question to a researcher consulting us for advice, usually on how best to
analyze their data, was almost invariably “What is the question you want to answer?” It was amazing how few would-be
researchers had thought about that. Doug’s way of posing such questions and eliciting the answers enabled him to win the
confidence of medical researchers while being able to be critical of their work almost unobtrusively and directing them
to better ways of doing the research.
His experience as a consulting statistician also inspired him to write his best-selling textbook Practical Statistics for
Medical Research (PSMR). I can personally vouch that the task took himmore than 10 years of intermittent but determined
effort fitted around his “day job.” I recall him discussing with me how hard it was to find appropriate real data sets to
illustrate statistical methods and principles in a direct and approachable way. He was absolutely determined to use only
real-data examples throughout the book, a distinctive feature of the work. In my view and that of many clinicians, PSMR
remains one of the best and most approachable texts of its type on the market. The ideas and approaches in the book
also inspired a short course with the same name, which still runs to this day (see https://www.ucl.ac.uk/statistics/psmr).
He was an inspiring teacher. His determination to use real examples shows he was grounded in actual research and the
many issues it can throw up rather than being the type of statistician who was interested only in numbers or abstract
mathematics.
We both left the CRC for new jobs on the same day (February 4, 1988). Our interests had developed rather differently over
the decade at the CRC. Doug had become more and more passionate about improving the quality of medical research. I
was inspiredmore by developingmethodological issues inmedical statistics, always with a view to transparency, common
sense, and practical usefulness. Therewith arose my strong and continuing interest in statistical software and algorithms
to embody and make accessible new techniques that promote good statistical practice. Although our paths subsequently
diverged in terms of different roles and different places, we continued to collaborate successfully (and enjoyably) on mat-
ters of mutual interest essentially until his untimely death in 2018.
On any topic he was always able to see the big picture underlying a detailed methodological research effort. That was
hugely helpful to a researcher like me.
On a personal level, Doug was a delight to have as a friend. He and I spoke, corresponded with and most importantly,
met in person many times over our working and private lives. He had an enormous sense of fun and a spirit-lifting,
infectious laugh. He had this characteristic way of throwing his head back as he laughed which made you want to
join in, even if it took you a second or two to catch up and realize what his quick brain had spotted was the funny
point of what you were discussing. He was amused and amusing without trivializing important questions. Yet, he could
complain vocally and bitterly when something rather minor was not going his way. (I think he felt assaulted in the amour
propre.)
One quirk that accorded beautifully with our research interests was his struggle with the cutpoint issue in daily life.
For example, Doug loved photography and good-quality cameras. Suppose he was considering buying a new camera
and had to decide how much to spend. What upper limit should he place on the price he was willing to pay? Dearer
usually means better, but why not go even dearer (or cheaper)? Or even (seemingly) simpler still, when in a supermarket,
which wine to choose? I do not think he ever really overcame the torment of such cutpoint placement issues. His
family acknowledged his ability to look at lots of restaurants before returning to the first he had seen to actually
eat!
In conclusion, itwas a terrible loss for a hugenumber of people, includingme,whenDougdied fromadvanced colorectal
cancer at the relatively young age of 69. He would undoubtedly have continued to contribute in a significant way to the
quality and effectiveness of medical research, ultimately to the benefit of patients. On a human level, he was terrific fun
to spend time with, and I miss him sorely.
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7 SUMMARY
Doug was the one of the first to review the statistical methods used in medical journals. Although reviewing statistical
methodology in peer review is standard today, his 1982 overview and 1991 review of developments in the previous decade
were lone voices (Altman, 1982, 1991c). Today, systematic reviews are considered a key task for researchers and overviews
are usually conducted by cooperative groups, but Doug did this hardwork on his own. It seems thatmany of his colleagues
did not recognize the importance of this work or did not see it as something that could be funded.
As he so clearly expressed in his scandal article, Dougwas convinced that the use of suitable statisticalmethodswas a key
issue in improvingmedical research (Altman, 1994).However, his early experience of statistical review formedical journals
was negative, as he found “..limited evidence of its effectiveness . . . ” (Altman, 1998). Assessing the statistical reviewing
policies of medical journals, Goodman, Altman, and George (1998) concluded “Except in the largest circulation medical
journals, the probability of formal methodological review of original research is fairly low. As readers and researchers depend
on the journals to assess the validity of the statistical methods and logic used in published reports, this is potentially a serious
problem.”
Doug became deeply involved in the new movement for reporting guidelines and was one of its leading researchers
when this topic was still ignored by most researchers and, to the best of our knowledge, the ISCB. The first invited ISCB
session on this topic, entitled “Unbiased reporting, integrity and ethics,” was in 2015 in Utrecht, with Willi as a coor-
ganizer and Doug, Patrick Bossuyt, and Lisa McShane as speakers. Today, it is becoming more accepted that “Report-
ing research is as important a part of a study as its design or analysis” (Jordan & Lewis, 2009). However, even excellent
reporting does not help if a study is badly designed or analyzed. In response, the STRATOS initiative (Sauerbrei et al.,
2014) aims to provide accessible and accurate guidance for relevant topics in the design and analysis of observational
studies.
In 2000, Doug wrote about areas of medical statistics that had gained prominence in the 1990s (Altman, 2000). Unfor-
tunately, his broad observations would still be true today:
(i) The misuse of statistics is very important.
(ii) A general climate of sloppiness is bad for science.
(iii) Statistics ismuchmore subjective (and difficult) than is usually acknowledged (this is why statisticians have not been
replaced by computers).
(iv) Major improvements in the quality of research published in medical journals are unlikely in the present research
climate.
(v) Too much research is done primarily to benefit the careers of researchers.
(vi) It need not be like this!
No, it need not be like this! Since the publication of these statements, Doug has inspired many colleagues and younger
students with his visionary thoughts. Many have followed in his steps to improve the use of statistics in medical research.
Wehope that this article inspires you to followDoug’s ideas to improve the quality ofmethodological andmedical research.
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